NCT06403267

NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis With or Without Endovascular Thrombectomy

Name: Clinical Trial NCT06403267
Creator: NoNO Inc.
Keywords: Acute Ischemic Stroke, NoNO-42, Phase 2, drug, clinical trial

A Multicentre, Prospective, Randomized, Open Label, Blinded-Endpoint, Placebo-controlled, Single-dose Trial to Determine the Efficacy and Safety of NoNO-42 in Participants With Acute Ischemic Stroke Selected for Thrombolysis With or Without Endovascular Thrombectomy (ACT-42 Trial)

NoNO Inc.·Phase 2·ClinicalTrials.gov·drugNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Acute Ischemic Stroke
Drug/Device/Intervention: NoNO-42
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: NoNO Inc.

Timeline & enrollment

Phase: Phase 2
Start date: May 01, 2024
End date: May 01, 2026
Enrollment: 600 participants

Primary outcome

Reducing global disability in participants with acute ischemic stroke (AIS)

Summary

ACT-42 is a domain of the ACT-GLOBAL platform (NCT06352632).  This trial is a Phase 2b, multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled single-dose adaptive trial.  A total of up to 600 male and female participants aged ≥ 45 to ≤ 90 years harboring an acute ischemic stroke who are eligible for an intravenous thrombolytic with or without endovascular thrombectomy therapy will be enrolled within 3 hours of stroke onset/last known well.

ICD-10 classifications

Stroke, not specified as haemorrhage or infarctionSequelae of stroke, not specified as haemorrhage or infarctionCerebral infarctionCerebral infarction, unspecifiedTransient cerebral ischaemic attack, unspecified

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06403267
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06403267 through Pure Global AI's free database. This Phase 2 trial is sponsored by NoNO Inc. and is currently Not yet recruiting. The study focuses on Acute Ischemic Stroke. Target enrollment is 600 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.